Skip to main content
Top
Published in: American Journal of Clinical Dermatology 5/2002

01-08-2002 | Current Opinion

Vitiligo

A Manifestation of Apoptosis?

Authors: Carol L. Huang, Dr James J. Nordlund, Raymond Boissy

Published in: American Journal of Clinical Dermatology | Issue 5/2002

Login to get access

Abstract

Vitiligo is a common cutaneous disorder that has significant biological and social consequences for those affected. It is characterized by a loss of melanocytes from the epidermis, which results in the absence of melanin, i.e. depigmentation. There are numerous hypotheses about the etiology of vitiligo, but no data to definitively prove one theory over another. It is likely that there are numerous causes for the loss of these melanocytes.
One way to approach the identification of the etiology is to determine the mechanism by which the melanocytes are destroyed. The two known mechanisms for the destruction of cells are necrosis and apoptosis. One purpose of this paper is to review the extant data that might suggest which of the two mechanisms is operative against melanocytes in patients with vitiligo. The histological data, and some laboratory data, support apoptosis, rather than necrosis, as the mechanism for removal of melanocytes. Apoptosis can be induced by a variety of factors, including immune cytokines, some environmental chemicals (for example substituted hydroquinones such as monobenzone) or other molecular mechanisms. Current therapies, such as corticosteroids and ultraviolet light, do affect apoptosis in a variety of ways.
Confirmation of apoptosis as a mechanism, and identification of how apoptosis is initiated to produce vitiligo, can serve as a basis for devising medications that might stop the progression of the disorder. The problem of vitiligo would be essentially solved if there was a medication that is well tolerated in children, adults and pregnant women, and that would halt the progression of the depigmentation. The study of apoptosis, mechanisms of its induction, and the ways to block apoptosis, is one possible way to find both the causes of depigmentation and medications to prevent its progression.
Literature
1.
go back to reference Nordlund J., Ortonne J. Mechanisms that cause abnormal skin color. In: Nordlund J., Boissy R., King R., et al., editors. The pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 489–502 Nordlund J., Ortonne J. Mechanisms that cause abnormal skin color. In: Nordlund J., Boissy R., King R., et al., editors. The pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 489–502
2.
go back to reference Boissy R., Nordlund J. Albinism. Dermatology in eMedicine [online]. James W., Elston D., editors. eMedicine Corporation, St. Petersburg. Available from URL: http://www.emedicine.com/derm/index/shtml [Accessed 2002 May 02] Boissy R., Nordlund J. Albinism. Dermatology in eMedicine [online]. James W., Elston D., editors. eMedicine Corporation, St. Petersburg. Available from URL: http://​www.​emedicine.​com/​derm/​index/​shtml [Accessed 2002 May 02]
3.
go back to reference Boissy R.E., Nordlund J.J. Molecular basis of congenital hypopigmentary disorders in humans: a review. Pigment Cell Res 1997; 10 (1-2): 12–24PubMedCrossRef Boissy R.E., Nordlund J.J. Molecular basis of congenital hypopigmentary disorders in humans: a review. Pigment Cell Res 1997; 10 (1-2): 12–24PubMedCrossRef
4.
go back to reference Spritz R.A. Piebaldism, Waardenburg syndrome and related genetic disorders of melanocyte development: clinical aspects. In: Nordlund J.J., Boissy R., Hearing V., et al., editors. The pigmentary system: physiology and pathophysiology. New York: Oxford University Press, 1998: 997 Spritz R.A. Piebaldism, Waardenburg syndrome and related genetic disorders of melanocyte development: clinical aspects. In: Nordlund J.J., Boissy R., Hearing V., et al., editors. The pigmentary system: physiology and pathophysiology. New York: Oxford University Press, 1998: 997
5.
go back to reference Nordlund J., Ortonne J. Disorders of hypopigmentation and depigmentation. In: Nordlund J., Boissy R., King R., et al., editors. Pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 503–707 Nordlund J., Ortonne J. Disorders of hypopigmentation and depigmentation. In: Nordlund J., Boissy R., King R., et al., editors. Pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 503–707
6.
go back to reference Sheth P. The differential diagnosis of vitiligo vulgaris. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 101–122 Sheth P. The differential diagnosis of vitiligo vulgaris. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 101–122
7.
go back to reference Tobin D., Swanson N., Pittelkow M.R., et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000; 191: 407–416PubMedCrossRef Tobin D., Swanson N., Pittelkow M.R., et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000; 191: 407–416PubMedCrossRef
8.
go back to reference Birbeck M.S., Breathnach A.S., Everall J.D. An electron microscope study of basal melanocytes and high-level clears cells (Langerhans cells) in vitiligo. J Invest Dermatol 1961; 37: 51–64 Birbeck M.S., Breathnach A.S., Everall J.D. An electron microscope study of basal melanocytes and high-level clears cells (Langerhans cells) in vitiligo. J Invest Dermatol 1961; 37: 51–64
9.
go back to reference Koh H.K., Sober A.J., Nakagawa H., et al. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol 1983; 9 (5): 696–708PubMedCrossRef Koh H.K., Sober A.J., Nakagawa H., et al. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol 1983; 9 (5): 696–708PubMedCrossRef
10.
go back to reference Le Poole I.C., van den Wijngaard R.M., Westerhof W., et al. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol 1993; 100 (6): 816–822PubMedCrossRef Le Poole I.C., van den Wijngaard R.M., Westerhof W., et al. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol 1993; 100 (6): 816–822PubMedCrossRef
11.
go back to reference Dippel E., Haas N., Grabbe J., et al. Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo. Br J Dermatol 1995; 132 (2): 182–189PubMedCrossRef Dippel E., Haas N., Grabbe J., et al. Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo. Br J Dermatol 1995; 132 (2): 182–189PubMedCrossRef
12.
go back to reference Ito K. Ultrastructural observations of dendritic cells in the repigmented area of vitiligo: electron microscopic studies on dopa oxidase in melanocytes which are present between the epidermal basal cells in the repigmented area of vitiligo. Jap J Dermatol 1975; 85 (6): 333–349 Ito K. Ultrastructural observations of dendritic cells in the repigmented area of vitiligo: electron microscopic studies on dopa oxidase in melanocytes which are present between the epidermal basal cells in the repigmented area of vitiligo. Jap J Dermatol 1975; 85 (6): 333–349
13.
go back to reference Bleehen S.S. The treatment of vitiligo with topical corticosteroids: light and electronmicroscopic studies. Br J Dermatol 1976; 94 Suppl. 12: 43–50PubMedCrossRef Bleehen S.S. The treatment of vitiligo with topical corticosteroids: light and electronmicroscopic studies. Br J Dermatol 1976; 94 Suppl. 12: 43–50PubMedCrossRef
14.
go back to reference Morohashi M., Hashimoto K., Goodman Jr T.F., et al. Ultrastructural studies of vitiligo, Vogt-Koyanagi syndrome, and incontinentia pigmenti achromians. Arch Dermatol 1977; 13 (6): 755–766CrossRef Morohashi M., Hashimoto K., Goodman Jr T.F., et al. Ultrastructural studies of vitiligo, Vogt-Koyanagi syndrome, and incontinentia pigmenti achromians. Arch Dermatol 1977; 13 (6): 755–766CrossRef
15.
go back to reference Moellmann G., Klein-Angerer S., Scollay D.A., et al. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol 1982; 79 (5): 321–330PubMedCrossRef Moellmann G., Klein-Angerer S., Scollay D.A., et al. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol 1982; 79 (5): 321–330PubMedCrossRef
16.
go back to reference Boissy R.E., Beato K.E., Nordlund J.J., et al. Dilated rough endoplasmic reticulum and premature death in melanocytes cultured from the vitiligo mouse. Am J Pathol 1991; 138 (6): 1511–1525PubMed Boissy R.E., Beato K.E., Nordlund J.J., et al. Dilated rough endoplasmic reticulum and premature death in melanocytes cultured from the vitiligo mouse. Am J Pathol 1991; 138 (6): 1511–1525PubMed
17.
go back to reference Boissy R.E., Liu Y.Y., Medrano E.E., et al. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol 1991; 97 (3): 395–404PubMedCrossRef Boissy R.E., Liu Y.Y., Medrano E.E., et al. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol 1991; 97 (3): 395–404PubMedCrossRef
18.
go back to reference Boissy R. Histology of vitiliginous skin. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 23–34 Boissy R. Histology of vitiliginous skin. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 23–34
19.
go back to reference Medrano E.E., Nordlund J.J. Successful culture of adult human melanocytes obtained from normal and vitiligo donors. J Invest Dermatol 1990; 95 (4): 441–445PubMed Medrano E.E., Nordlund J.J. Successful culture of adult human melanocytes obtained from normal and vitiligo donors. J Invest Dermatol 1990; 95 (4): 441–445PubMed
20.
go back to reference Cui J., Shen L.Y., Wang G.C., et al. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991; 97 (3): 410–416PubMedCrossRef Cui J., Shen L.Y., Wang G.C., et al. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991; 97 (3): 410–416PubMedCrossRef
21.
go back to reference Cui J. The melanocyte reservoir and its necessity. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 163–165 Cui J. The melanocyte reservoir and its necessity. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 163–165
22.
go back to reference Ortonne J.P., MacDonald D.M., Micoud A., et al. PUVA-induced repigmentation of vitiligo: a histochemical (split-DOPA) and ultrastructural study. Br J Dermatol 1979; 101 (1): 1–12PubMedCrossRef Ortonne J.P., MacDonald D.M., Micoud A., et al. PUVA-induced repigmentation of vitiligo: a histochemical (split-DOPA) and ultrastructural study. Br J Dermatol 1979; 101 (1): 1–12PubMedCrossRef
23.
go back to reference Ortonne J.P., Schmitt D., Thivolet J., et al. PUVA-induced repigmentation of vitiligo: scanning electron microscopy of hair follicles. J Invest Dermatol 1980; 74 (1): 40–42PubMedCrossRef Ortonne J.P., Schmitt D., Thivolet J., et al. PUVA-induced repigmentation of vitiligo: scanning electron microscopy of hair follicles. J Invest Dermatol 1980; 74 (1): 40–42PubMedCrossRef
24.
go back to reference Galadari E., Mehregan A.H., Hashimoto K., et al. Ultrastructural study of vitiligo. Int J Dermatol 1993; 32 (4): 269–271PubMed Galadari E., Mehregan A.H., Hashimoto K., et al. Ultrastructural study of vitiligo. Int J Dermatol 1993; 32 (4): 269–271PubMed
25.
go back to reference Arrunategui A., Arroyo C., Garcia L., et al. Melanocyte reservoir in vitiligo. Int J Dermatol 1994; 33 (7): 484–487PubMedCrossRef Arrunategui A., Arroyo C., Garcia L., et al. Melanocyte reservoir in vitiligo. Int J Dermatol 1994; 33 (7): 484–487PubMedCrossRef
26.
go back to reference Nordlund J.J., Ortonne J.P. Vitiligo vulgaris. In: Nordlund J., Boissy R., King R., et al., editors. The pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 513–553 Nordlund J.J., Ortonne J.P. Vitiligo vulgaris. In: Nordlund J., Boissy R., King R., et al., editors. The pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 513–553
27.
go back to reference Halder R., Nordlund J. Surgical treatment of pigmentary disorders. In: Nordlund J., Boissy R., King R., et al., editors. The pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 987–994 Halder R., Nordlund J. Surgical treatment of pigmentary disorders. In: Nordlund J., Boissy R., King R., et al., editors. The pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 987–994
28.
go back to reference Falabella R. Surgical therapies for vitiligo. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 193–202 Falabella R. Surgical therapies for vitiligo. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 193–202
29.
go back to reference Malmusi M., Ackerman A. A critical review of apoptosis in historical perspective. Am J Dermatopathol 2000; 22: 291–293PubMedCrossRef Malmusi M., Ackerman A. A critical review of apoptosis in historical perspective. Am J Dermatopathol 2000; 22: 291–293PubMedCrossRef
30.
go back to reference Mishima Y., Kawasaki H., Pinkus H., et al. Dendritic cell dynamics in progressive depigmentations: distinctive cytokinetics of -dendritic cells revealed by electron microscopy. Arch Dermatol Forsch 1972; 243 (2): 67–87PubMed Mishima Y., Kawasaki H., Pinkus H., et al. Dendritic cell dynamics in progressive depigmentations: distinctive cytokinetics of -dendritic cells revealed by electron microscopy. Arch Dermatol Forsch 1972; 243 (2): 67–87PubMed
31.
go back to reference Abdel-Naser M.B., Kruger-Krasagakes S., Krasagakis K., et al. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res 1994; 7 (1): 1–8PubMedCrossRef Abdel-Naser M.B., Kruger-Krasagakes S., Krasagakis K., et al. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res 1994; 7 (1): 1–8PubMedCrossRef
32.
go back to reference Blois M. Phagocytosis of melanin particles by human epidermal cells in vitro. J Invest Dermatol 1968; 50: 336–337PubMed Blois M. Phagocytosis of melanin particles by human epidermal cells in vitro. J Invest Dermatol 1968; 50: 336–337PubMed
33.
go back to reference Wolff K., Konrad K. Melanin pigmentation: an in vivo model for studies of melanosome kinetics within keratinocytes. Science 1971; 174: 1034–1035PubMedCrossRef Wolff K., Konrad K. Melanin pigmentation: an in vivo model for studies of melanosome kinetics within keratinocytes. Science 1971; 174: 1034–1035PubMedCrossRef
34.
35.
go back to reference Cummings M., Nordlund J.J. Chemical leukoderma: fact or fancy. Am J Contact Derm 1995; 6: 122–127CrossRef Cummings M., Nordlund J.J. Chemical leukoderma: fact or fancy. Am J Contact Derm 1995; 6: 122–127CrossRef
36.
go back to reference Gellin G.A., Possick P.A., Perone V.B., et al. Depigmentation from 4-tertiary butyl catechol: an experimental study. J Invest Dermatol 1970; 55: 190–197PubMedCrossRef Gellin G.A., Possick P.A., Perone V.B., et al. Depigmentation from 4-tertiary butyl catechol: an experimental study. J Invest Dermatol 1970; 55: 190–197PubMedCrossRef
37.
38.
go back to reference Oliver E.A., Schwartz L. Occupational leukoderma. Arch Dermatol Syph 1940; 42: 993–1014CrossRef Oliver E.A., Schwartz L. Occupational leukoderma. Arch Dermatol Syph 1940; 42: 993–1014CrossRef
39.
go back to reference Malten K.E., Seutter E. Occupational vitiligo due to paratertiary butylphenol and homologues. Trans St Johns Hosp Dermatol Soc 1971; 57 (1): 115–134PubMed Malten K.E., Seutter E. Occupational vitiligo due to paratertiary butylphenol and homologues. Trans St Johns Hosp Dermatol Soc 1971; 57 (1): 115–134PubMed
40.
go back to reference Calnan C.D. Occupational leukoderma from alkyl phenols. Proc R Soc Med 1973; 66 (3): 258–260PubMed Calnan C.D. Occupational leukoderma from alkyl phenols. Proc R Soc Med 1973; 66 (3): 258–260PubMed
41.
go back to reference Bentley-Phillips R. Occupational leucoderma following misuse of a disinfectant. South Afr Med J 1974; 48 (19): 810 Bentley-Phillips R. Occupational leucoderma following misuse of a disinfectant. South Afr Med J 1974; 48 (19): 810
42.
go back to reference Goldmann P.J., Thiess A.M. Occupational vitiligo caused by para-tertiary-butylphenol, a trial of vitiligo, hepatosis and struma. Hautarzt 1976; 27 (4): 155–159PubMed Goldmann P.J., Thiess A.M. Occupational vitiligo caused by para-tertiary-butylphenol, a trial of vitiligo, hepatosis and struma. Hautarzt 1976; 27 (4): 155–159PubMed
43.
go back to reference Rodermund O.E. Occupational vitiligo caused by paratertiary butylphenol [letter]. Arch Dermatol 1976; 112 (4): 554–555PubMedCrossRef Rodermund O.E. Occupational vitiligo caused by paratertiary butylphenol [letter]. Arch Dermatol 1976; 112 (4): 554–555PubMedCrossRef
44.
go back to reference James O., Mayes R.W., Stevenson C.J., et al. Occupational vitiligo induced by p-tertbutylphenol, a systemic disease? Lancet 1977; II (8050): 1217–1219CrossRef James O., Mayes R.W., Stevenson C.J., et al. Occupational vitiligo induced by p-tertbutylphenol, a systemic disease? Lancet 1977; II (8050): 1217–1219CrossRef
45.
go back to reference Ebner H., Helletzgruber M., Hofer R., et al. Vitiligo from p-tert butylphenol; a contribution to the problem of the internal manifestations of this occupational disease [in German]. Derm Beruf Umwelt 1979; 27 (4): 99–104PubMed Ebner H., Helletzgruber M., Hofer R., et al. Vitiligo from p-tert butylphenol; a contribution to the problem of the internal manifestations of this occupational disease [in German]. Derm Beruf Umwelt 1979; 27 (4): 99–104PubMed
46.
go back to reference Gellin G.A., Maibach H.I., Misiaszek M.H., et al. Detection of environmental depigmenting substances. Contact Dermatitis 1979; 5 (4): 201–213PubMedCrossRef Gellin G.A., Maibach H.I., Misiaszek M.H., et al. Detection of environmental depigmenting substances. Contact Dermatitis 1979; 5 (4): 201–213PubMedCrossRef
47.
go back to reference Arievich A.M., Selisskii G.D. Occupational vitiligo. Vestn Dermatol Venerol 1980; (5): 46–49PubMed Arievich A.M., Selisskii G.D. Occupational vitiligo. Vestn Dermatol Venerol 1980; (5): 46–49PubMed
48.
go back to reference Frenk E., Loi-Zedda P. Occupational depigmentation due to a hydroquinone-containing photographic developer. Contact Dermatitis 1980; 6 (3): 238–239PubMedCrossRef Frenk E., Loi-Zedda P. Occupational depigmentation due to a hydroquinone-containing photographic developer. Contact Dermatitis 1980; 6 (3): 238–239PubMedCrossRef
49.
go back to reference Swarbrick P. Vitiligo as an occupational disease. Occup Health (Lond) 1980; 32 (9): 442–448 Swarbrick P. Vitiligo as an occupational disease. Occup Health (Lond) 1980; 32 (9): 442–448
50.
go back to reference O’Sullivan J.J., Stevenson C.J. Screening for occupational vitiligo in workers exposed to hydroquinone monomethyl ether and to paratertiary-amyl-phenol. Br J Ind Med 1981; 38 (4): 381–383PubMed O’Sullivan J.J., Stevenson C.J. Screening for occupational vitiligo in workers exposed to hydroquinone monomethyl ether and to paratertiary-amyl-phenol. Br J Ind Med 1981; 38 (4): 381–383PubMed
51.
go back to reference Romaguera C., Grimalt F. Occupational leukoderma and contact dermatitis from paratertiary-butylphenol. Contact Dermatitis 1981; 7 (3): 159–160PubMedCrossRef Romaguera C., Grimalt F. Occupational leukoderma and contact dermatitis from paratertiary-butylphenol. Contact Dermatitis 1981; 7 (3): 159–160PubMedCrossRef
52.
go back to reference Stevenson C.J. Occupational vitiligo: clinical and epidemiological aspects. Br J Dermatol 1981; 105 Suppl. 21: 51–56PubMedCrossRef Stevenson C.J. Occupational vitiligo: clinical and epidemiological aspects. Br J Dermatol 1981; 105 Suppl. 21: 51–56PubMedCrossRef
53.
go back to reference Goette D.K. Raccoon-like periorbital leukoderma from contact with swim goggles. Contact Dermatitis 1984; 10 (3): 129–131PubMedCrossRef Goette D.K. Raccoon-like periorbital leukoderma from contact with swim goggles. Contact Dermatitis 1984; 10 (3): 129–131PubMedCrossRef
54.
go back to reference Das M., Tandon A. Occupational vitiligo. Contact Dermatitis 1988; 19: 184–185CrossRef Das M., Tandon A. Occupational vitiligo. Contact Dermatitis 1988; 19: 184–185CrossRef
55.
go back to reference O’Malley M.A., Mathias C.G., Priddy M., et al. Occupational vitiligo due to unsuspected presence of phenolic antioxidant byproducts in commercial bulk rubber. J Occup Med 1988; 30 (6): 512–516PubMedCrossRef O’Malley M.A., Mathias C.G., Priddy M., et al. Occupational vitiligo due to unsuspected presence of phenolic antioxidant byproducts in commercial bulk rubber. J Occup Med 1988; 30 (6): 512–516PubMedCrossRef
56.
go back to reference Gawkrodger D.J., Cork M.J., Bleehan S.S., et al. Occupational vitiligo and contact sensitivity to para-tertiary butyl catechol. Contact Dermatitis 1991; 25 (3): 200–201PubMedCrossRef Gawkrodger D.J., Cork M.J., Bleehan S.S., et al. Occupational vitiligo and contact sensitivity to para-tertiary butyl catechol. Contact Dermatitis 1991; 25 (3): 200–201PubMedCrossRef
57.
go back to reference Tosti A., Gaddoni G., Piracinni B.M., et al. Occupational leukoderma due to phenolic compounds in the ceramics industry? Contact Dermatitis 1991; 25 (1): 67–68PubMedCrossRef Tosti A., Gaddoni G., Piracinni B.M., et al. Occupational leukoderma due to phenolic compounds in the ceramics industry? Contact Dermatitis 1991; 25 (1): 67–68PubMedCrossRef
58.
go back to reference Jimbow K., Obata H., Pathak M.A., et al. Mechanism of depigmentation by hydroquinone. J Invest Dermatol 1974; 62 (4): 436–449PubMedCrossRef Jimbow K., Obata H., Pathak M.A., et al. Mechanism of depigmentation by hydroquinone. J Invest Dermatol 1974; 62 (4): 436–449PubMedCrossRef
59.
go back to reference Mans D., Lafleur M., Westmijze E.J., et al. Reactions of glutathione with the catechol, the ortho-quinone and semi-quinone free radical of etoposide: consequences for DNA inactivation. Biochem Pharmacol 1992; 43: 1761–1768PubMedCrossRef Mans D., Lafleur M., Westmijze E.J., et al. Reactions of glutathione with the catechol, the ortho-quinone and semi-quinone free radical of etoposide: consequences for DNA inactivation. Biochem Pharmacol 1992; 43: 1761–1768PubMedCrossRef
60.
go back to reference Halliwell B., Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 1993; 57 Suppl. 5: 715S–724SPubMed Halliwell B., Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 1993; 57 Suppl. 5: 715S–724SPubMed
61.
go back to reference Nakagawa Y., Tayama S., Moore G., et al. Cytotoxic effects of biphenyl and hydroxybiphenyls on isolated rat hepatocytes. Biochem Pharmacol 1993; 45: 1959–1965PubMedCrossRef Nakagawa Y., Tayama S., Moore G., et al. Cytotoxic effects of biphenyl and hydroxybiphenyls on isolated rat hepatocytes. Biochem Pharmacol 1993; 45: 1959–1965PubMedCrossRef
62.
go back to reference Yang F., Abdel Malek Z., Boissy R.E., et al. Effects of commonly used mitogens on the cytotoxicity of 4-tertiary-butylphenol to human melanocytes. In Vitro Cell Dev Biol Anim 1999; 35: 566–570PubMedCrossRef Yang F., Abdel Malek Z., Boissy R.E., et al. Effects of commonly used mitogens on the cytotoxicity of 4-tertiary-butylphenol to human melanocytes. In Vitro Cell Dev Biol Anim 1999; 35: 566–570PubMedCrossRef
63.
go back to reference Yang F., Sarangarajan R., Le Poole I.C., et al. The cytotoxicity and apoptosis induced by 4-tertiary butylphenol in human melanocytes are independent of tyrosinase activity. J Invest Dermatol 2000; 114: 157–164PubMedCrossRef Yang F., Sarangarajan R., Le Poole I.C., et al. The cytotoxicity and apoptosis induced by 4-tertiary butylphenol in human melanocytes are independent of tyrosinase activity. J Invest Dermatol 2000; 114: 157–164PubMedCrossRef
64.
go back to reference Yang F., Bossy R. Effects of 4-tertiary butylphenol on the tyrosinase activity in human melanocytes. Pigment Cell Res 1999; 12: 237–245PubMedCrossRef Yang F., Bossy R. Effects of 4-tertiary butylphenol on the tyrosinase activity in human melanocytes. Pigment Cell Res 1999; 12: 237–245PubMedCrossRef
65.
go back to reference Ros J., Rodrigues-Lopex J., Varon R., et al. Kinetic study of the oxidation of 4-tertbutyl phenol by tyrosinase. Eur J Biochem 1994; 222: 449–452PubMedCrossRef Ros J., Rodrigues-Lopex J., Varon R., et al. Kinetic study of the oxidation of 4-tertbutyl phenol by tyrosinase. Eur J Biochem 1994; 222: 449–452PubMedCrossRef
66.
go back to reference Jimenez M., Garcia-Carmona G. Hydrogen peroxide-dependent 4 t-butylphenol hydroxylation by tyrosinase: a new catalytic activity. Biochim Biophys Acta 1996; 1287: 33–39CrossRef Jimenez M., Garcia-Carmona G. Hydrogen peroxide-dependent 4 t-butylphenol hydroxylation by tyrosinase: a new catalytic activity. Biochim Biophys Acta 1996; 1287: 33–39CrossRef
67.
go back to reference Thorneby-Andersson K., Sterner O., Hansson C.L. Tyrosinase-mediated formation of a reactive quinone from the depigmenting agents, 4-tert butylphenol and 4 tert butylcatechol. Pigment Cell Res 2000; 13: 33–38PubMedCrossRef Thorneby-Andersson K., Sterner O., Hansson C.L. Tyrosinase-mediated formation of a reactive quinone from the depigmenting agents, 4-tert butylphenol and 4 tert butylcatechol. Pigment Cell Res 2000; 13: 33–38PubMedCrossRef
68.
go back to reference Orrechia G. Alternative therapies for vitiligo. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 222–242 Orrechia G. Alternative therapies for vitiligo. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 222–242
69.
go back to reference Schallreuter K., Moore J. Pseudocatalase in the treatment of vitiligo. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 182–192 Schallreuter K., Moore J. Pseudocatalase in the treatment of vitiligo. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 182–192
70.
go back to reference Okamoto H., Mizuno K., Itoh T., et al. Evaluation of apoptotic cells induced by ultraviolet light B radiation in epidermal sheets stained by the TUNEL technique. J Invest Dermatol 1999; 113: 802–807PubMedCrossRef Okamoto H., Mizuno K., Itoh T., et al. Evaluation of apoptotic cells induced by ultraviolet light B radiation in epidermal sheets stained by the TUNEL technique. J Invest Dermatol 1999; 113: 802–807PubMedCrossRef
71.
go back to reference Van Den Wijngaard R., Aten J., Scheepmaker A., et al. Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br J Dermatol 2000; 143: 573–581PubMedCrossRef Van Den Wijngaard R., Aten J., Scheepmaker A., et al. Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br J Dermatol 2000; 143: 573–581PubMedCrossRef
72.
go back to reference Parrish J.A., Fitzpatrick T.B., Shea C., et al. Photochemotherapy of vitiligo: use of orally administered psoralens and a high-intensity long-wave ultraviolet light system. Arch Dermatol 1976; 112 (11): 1531–1534PubMedCrossRef Parrish J.A., Fitzpatrick T.B., Shea C., et al. Photochemotherapy of vitiligo: use of orally administered psoralens and a high-intensity long-wave ultraviolet light system. Arch Dermatol 1976; 112 (11): 1531–1534PubMedCrossRef
73.
go back to reference Theodoridis A., Tsambaos D., Sivenas C. Oral trimethylpsoralen in the treatment of vitiligo. Acta Dermatol Venereol 1976; 56 (3): 253–256 Theodoridis A., Tsambaos D., Sivenas C. Oral trimethylpsoralen in the treatment of vitiligo. Acta Dermatol Venereol 1976; 56 (3): 253–256
74.
go back to reference Gupta A.K., Anderson T.F. Psoralen photochemotherapy. J Am Acad Dermatol 1987; 17 (5 Pt 1): 703–734PubMedCrossRef Gupta A.K., Anderson T.F. Psoralen photochemotherapy. J Am Acad Dermatol 1987; 17 (5 Pt 1): 703–734PubMedCrossRef
75.
go back to reference Tham S.N., Gange R.W., Parrish J.A. Ultraviolet-B treatment of psoriasis in patients with concomitant vitiligo [letter]. Arch Dermatol 1987; 123 (1): 26–27PubMedCrossRef Tham S.N., Gange R.W., Parrish J.A. Ultraviolet-B treatment of psoriasis in patients with concomitant vitiligo [letter]. Arch Dermatol 1987; 123 (1): 26–27PubMedCrossRef
76.
go back to reference Ortel B., Tanew A., Honigsmann H. Treatment of vitiligo with khellin and ultraviolet A. J Am Acad Dermatol 1988; 18 (4 Pt 1): 693–701PubMedCrossRef Ortel B., Tanew A., Honigsmann H. Treatment of vitiligo with khellin and ultraviolet A. J Am Acad Dermatol 1988; 18 (4 Pt 1): 693–701PubMedCrossRef
77.
go back to reference Honigsmann H. Phototherapy and photochemotherapy. Sem Dermatol 1990; 9 (1): 84–90 Honigsmann H. Phototherapy and photochemotherapy. Sem Dermatol 1990; 9 (1): 84–90
78.
79.
go back to reference Karppinen L., Lassus A. Treatment of vitiligo with 5-methoxypsoralen and selective ultraviolet phototherapy (SUP). Nouv Dermatol 1992; 11: 709–714 Karppinen L., Lassus A. Treatment of vitiligo with 5-methoxypsoralen and selective ultraviolet phototherapy (SUP). Nouv Dermatol 1992; 11: 709–714
80.
go back to reference Skouge J.W., Morison W.L., Diwan R.V., et al. Autografting and PUVA: a combination therapy for vitiligo. J Dermatol Surg Oncol 1992; 18 (5): 357–360PubMed Skouge J.W., Morison W.L., Diwan R.V., et al. Autografting and PUVA: a combination therapy for vitiligo. J Dermatol Surg Oncol 1992; 18 (5): 357–360PubMed
81.
go back to reference Imamura S., Tagami H. Treatment of vitiligo with oral corticosteroids. Dermatologica 1976; 153 (3): 179–185PubMedCrossRef Imamura S., Tagami H. Treatment of vitiligo with oral corticosteroids. Dermatologica 1976; 153 (3): 179–185PubMedCrossRef
82.
go back to reference Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984; 120 (5): 631–635PubMedCrossRef Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984; 120 (5): 631–635PubMedCrossRef
83.
go back to reference Goldstein E., Haberman H.F., Menon I.A., et al. Non-psoralen treatment of vitiligo; part I: cosmetics, systemic coloring agents, and corticosteroids. Int J Dermatol 1992; 31 (4): 229–236PubMedCrossRef Goldstein E., Haberman H.F., Menon I.A., et al. Non-psoralen treatment of vitiligo; part I: cosmetics, systemic coloring agents, and corticosteroids. Int J Dermatol 1992; 31 (4): 229–236PubMedCrossRef
84.
go back to reference Pasricha J.S., Khaitan B.K. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol 1993; 32 (10): 753–757PubMedCrossRef Pasricha J.S., Khaitan B.K. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol 1993; 32 (10): 753–757PubMedCrossRef
85.
86.
go back to reference McKay B., Chen F., Perumalswami C.R., et al. The tumor suppressor p53 can both stimulate and inhibit ultraviolet light-induced apoptosis. Mol Biol Cell 2000; 11: 2543–2551PubMed McKay B., Chen F., Perumalswami C.R., et al. The tumor suppressor p53 can both stimulate and inhibit ultraviolet light-induced apoptosis. Mol Biol Cell 2000; 11: 2543–2551PubMed
87.
go back to reference Zhai S., Yaar M., Doyle S.M., et al. Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Exp Cell Res 1996; 224: 335–343PubMedCrossRef Zhai S., Yaar M., Doyle S.M., et al. Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Exp Cell Res 1996; 224: 335–343PubMedCrossRef
88.
go back to reference Petit-Frere C., Capulas E., Lyon D.A., et al. Apoptosis and cytokine release induced by ionizing or ultraviolet B radiation in primary and immortalized human keratinocytes. Carcinogenesis 2000; 21: 1087–1095PubMedCrossRef Petit-Frere C., Capulas E., Lyon D.A., et al. Apoptosis and cytokine release induced by ionizing or ultraviolet B radiation in primary and immortalized human keratinocytes. Carcinogenesis 2000; 21: 1087–1095PubMedCrossRef
89.
go back to reference Hofs T. Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells. Folia Haematol Int Mag Klin Morphol Blutforsch 1982; 109 (2): 244–250PubMed Hofs T. Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells. Folia Haematol Int Mag Klin Morphol Blutforsch 1982; 109 (2): 244–250PubMed
90.
go back to reference Naughton G.K., Eisinger M., Bystryn J.C. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983; 81 (6): 540–542PubMedCrossRef Naughton G.K., Eisinger M., Bystryn J.C. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983; 81 (6): 540–542PubMedCrossRef
91.
go back to reference Betterle C., Mirakian R., Doniach D., et al. Antibodies to melanocytes in vitiligo [letter]. Lancet 1984; I (8369): 159CrossRef Betterle C., Mirakian R., Doniach D., et al. Antibodies to melanocytes in vitiligo [letter]. Lancet 1984; I (8369): 159CrossRef
92.
go back to reference Naughton G.K., Lipkin G., Bystryn J.C. Expression of vitiligo antigen on a revertant line of hamster melanoma cells. J Invest Dermatol 1984; 83 (5): 317–319PubMedCrossRef Naughton G.K., Lipkin G., Bystryn J.C. Expression of vitiligo antigen on a revertant line of hamster melanoma cells. J Invest Dermatol 1984; 83 (5): 317–319PubMedCrossRef
93.
go back to reference Bystryn J.C., Naughton G.K. The significance of vitiligo antibodies. J Dermatol 1985; 12 (1): 1–9PubMedCrossRef Bystryn J.C., Naughton G.K. The significance of vitiligo antibodies. J Dermatol 1985; 12 (1): 1–9PubMedCrossRef
94.
go back to reference Morgan M, Castells A., Ramirez A. Autoantibodies in vitiligo: clinical significance [in Spanish]. Med Cutan Ibero Lat Am 1986; 14 (2): 139–142PubMed Morgan M, Castells A., Ramirez A. Autoantibodies in vitiligo: clinical significance [in Spanish]. Med Cutan Ibero Lat Am 1986; 14 (2): 139–142PubMed
95.
go back to reference Naughton G.K., Mahaffey M., Bystryn J.C. Antibodies to surface antigens of pigmented cells in animals with vitiligo. Proc Soc Exp Biol Med 1986; 181 (3): 423–426PubMed Naughton G.K., Mahaffey M., Bystryn J.C. Antibodies to surface antigens of pigmented cells in animals with vitiligo. Proc Soc Exp Biol Med 1986; 181 (3): 423–426PubMed
96.
go back to reference Naughton G.K., Reggiardo D., Bystryn J.C. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15 (5 Pt 1): 978–981PubMedCrossRef Naughton G.K., Reggiardo D., Bystryn J.C. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15 (5 Pt 1): 978–981PubMedCrossRef
97.
go back to reference Bystryn J.C., Pfeffer S. Vitiligo and antibodies to melanocytes. Prog Clin Biol Res 1988; 256: 195–206PubMed Bystryn J.C., Pfeffer S. Vitiligo and antibodies to melanocytes. Prog Clin Biol Res 1988; 256: 195–206PubMed
98.
go back to reference Norris D.A., Kissinger R.M., Naughton G.M., et al. Evidence for immunologic mechanisms in human vitiligo: patients sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90 (6): 783–789PubMedCrossRef Norris D.A., Kissinger R.M., Naughton G.M., et al. Evidence for immunologic mechanisms in human vitiligo: patients sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90 (6): 783–789PubMedCrossRef
99.
100.
go back to reference Cui J., Harning R., Henn M., et al. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992; 98 (2): 162–165PubMedCrossRef Cui J., Harning R., Henn M., et al. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992; 98 (2): 162–165PubMedCrossRef
101.
go back to reference Cui J., Arita Y., Bystryn J.C. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993; 100 (6): 812–815PubMedCrossRef Cui J., Arita Y., Bystryn J.C. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993; 100 (6): 812–815PubMedCrossRef
102.
go back to reference Fishman P., Azizi E., Schoenfeld Y., et al. Vitiligo autoantibodies are effective against melanoma. Cancer 1993; 72 (8): 2365–2369PubMedCrossRef Fishman P., Azizi E., Schoenfeld Y., et al. Vitiligo autoantibodies are effective against melanoma. Cancer 1993; 72 (8): 2365–2369PubMedCrossRef
103.
go back to reference Merimsky O., Shoenfeld Y., Chaitchik S., et al. Antigens and antibodies in malignant melanoma. Tumour Biol 1994; 15 (4): 188–202PubMedCrossRef Merimsky O., Shoenfeld Y., Chaitchik S., et al. Antigens and antibodies in malignant melanoma. Tumour Biol 1994; 15 (4): 188–202PubMedCrossRef
104.
go back to reference Song Y.H., Connor E., Li Y., et al. The role of tyrosinase in autoimmune vitiligo. Lancet 1994; 344 (8929): 1049–1052PubMedCrossRef Song Y.H., Connor E., Li Y., et al. The role of tyrosinase in autoimmune vitiligo. Lancet 1994; 344 (8929): 1049–1052PubMedCrossRef
105.
go back to reference Cui J., Arita Y., Bystryn J.C. Characterization of vitiligo antigens. Pigment Cell Res 1995; 8 (1): 53–59PubMedCrossRef Cui J., Arita Y., Bystryn J.C. Characterization of vitiligo antigens. Pigment Cell Res 1995; 8 (1): 53–59PubMedCrossRef
106.
go back to reference Cui J., Bystryn J.C. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 1995; 131 (3): 314–318PubMedCrossRef Cui J., Bystryn J.C. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 1995; 131 (3): 314–318PubMedCrossRef
107.
go back to reference Cui J., Chen D., Misfeldt M.L., et al. Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995; 8 (1): 60–63PubMedCrossRef Cui J., Chen D., Misfeldt M.L., et al. Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995; 8 (1): 60–63PubMedCrossRef
108.
go back to reference Gilhar A., Zelickson B., Ulman Y., et al. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995; 105 (5): 683–686PubMedCrossRef Gilhar A., Zelickson B., Ulman Y., et al. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995; 105 (5): 683–686PubMedCrossRef
109.
go back to reference Hara I., Takechi Y., Houghton A.N. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995; 182 (5): 1609–1614PubMedCrossRef Hara I., Takechi Y., Houghton A.N. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995; 182 (5): 1609–1614PubMedCrossRef
110.
go back to reference Kemp E.H., Gawkrodger D.J., Watson P.F., et al. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol 1997; 109 (3): 495–500PubMedCrossRef Kemp E.H., Gawkrodger D.J., Watson P.F., et al. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol 1997; 109 (3): 495–500PubMedCrossRef
111.
go back to reference Duvic M., Rapini R., Hoots W.K., et al. Human immunodeficiency virus-associated vitiligo: expression of autoimmunity with immunodeficiency? J Am Acad Dermatol 1987; 17 (4): 656–662PubMedCrossRef Duvic M., Rapini R., Hoots W.K., et al. Human immunodeficiency virus-associated vitiligo: expression of autoimmunity with immunodeficiency? J Am Acad Dermatol 1987; 17 (4): 656–662PubMedCrossRef
112.
go back to reference Spickett G., Prentice A.G., Wallington T., et al. Alopecia totalis and vitiligo in common variable immunodeficiency. Postgrad Med J 1991; 67 (785): 291–294PubMedCrossRef Spickett G., Prentice A.G., Wallington T., et al. Alopecia totalis and vitiligo in common variable immunodeficiency. Postgrad Med J 1991; 67 (785): 291–294PubMedCrossRef
113.
go back to reference Tojo N., Yoshimura N., Yoshizawa M. Vitiligo and chronic photosensitivity in human immunodeficiency virus infection. Jpn J Med 1991; 30 (3): 255–259PubMedCrossRef Tojo N., Yoshimura N., Yoshizawa M. Vitiligo and chronic photosensitivity in human immunodeficiency virus infection. Jpn J Med 1991; 30 (3): 255–259PubMedCrossRef
114.
go back to reference Tanus T., Levinson A.I., Atkins P.C. Polyautoimmune syndrome in common variable immunodeficiency. J Int Med 1993; 234 (5): 525–527CrossRef Tanus T., Levinson A.I., Atkins P.C. Polyautoimmune syndrome in common variable immunodeficiency. J Int Med 1993; 234 (5): 525–527CrossRef
115.
go back to reference Garcia-Patos Briones V., Rodriguez Cano L., Capdevila Morell J.A. Vitiligo associated with the acquired immunodeficiency syndrome [letter]. Med Clin 1994; 103 (9): 358 Garcia-Patos Briones V., Rodriguez Cano L., Capdevila Morell J.A. Vitiligo associated with the acquired immunodeficiency syndrome [letter]. Med Clin 1994; 103 (9): 358
116.
go back to reference Cho M., Cohen P.R., Duvic M. Vitiligo and alopecia areata in patients with human immunodeficiency virus infection. South Med J 1995; 88 (4): 489–491PubMedCrossRef Cho M., Cohen P.R., Duvic M. Vitiligo and alopecia areata in patients with human immunodeficiency virus infection. South Med J 1995; 88 (4): 489–491PubMedCrossRef
Metadata
Title
Vitiligo
A Manifestation of Apoptosis?
Authors
Carol L. Huang
Dr James J. Nordlund
Raymond Boissy
Publication date
01-08-2002
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 5/2002
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200203050-00001

Other articles of this Issue 5/2002

American Journal of Clinical Dermatology 5/2002 Go to the issue

Leading Article

Self-Tanning Lotions

Therapy in Practice

Cutaneous Tuberculosis